INVENTIVA ADS/1 O.N. - Asset Resilience Ratio
INVENTIVA ADS/1 O.N. (6IVA) has an Asset Resilience Ratio of 52.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of INVENTIVA ADS/1 O.N. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how INVENTIVA ADS/1 O.N.'s Asset Resilience Ratio has changed over time. See 6IVA book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down INVENTIVA ADS/1 O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 6IVA stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €131.56 Million | 52.73% |
| Total Liquid Assets | €131.56 Million | 52.73% |
Asset Resilience Insights
- Very High Liquidity: INVENTIVA ADS/1 O.N. maintains exceptional liquid asset reserves at 52.73% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
INVENTIVA ADS/1 O.N. Industry Peers by Asset Resilience Ratio
Compare INVENTIVA ADS/1 O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Sk Biopharmaceuticals Co Ltd
KO:326030 |
Biotechnology | 0.14% |
|
Crispr Therapeutics AG
NASDAQ:CRSP |
Biotechnology | 74.05% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Ascendis Pharma AS
F:A71 |
Biotechnology | 0.00% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 13.57% |
Annual Asset Resilience Ratio for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual Asset Resilience Ratio data for INVENTIVA ADS/1 O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 52.73% | €131.56 Million ≈ $153.81 Million |
€249.51 Million ≈ $291.70 Million |
-- |
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€118.97 Million ≈ $139.08 Million |
-- |
| 2023-12-31 | 0.10% | €70.00K ≈ $81.84K |
€69.56 Million ≈ $81.32 Million |
-0.80pp |
| 2022-12-31 | 0.90% | €1.05 Million ≈ $1.23 Million |
€116.00 Million ≈ $135.62 Million |
-6.33pp |
| 2021-12-31 | 7.24% | €8.83 Million ≈ $10.32 Million |
€121.98 Million ≈ $142.61 Million |
-- |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more